Ê׸ö°ÐÏò°×ϸ°û½éËØ23ÒÖÖƼÁÌØŵÑÅ£¨¹ÅÈûÆæÓȵ¥¿¹£©½ñÈÕÔÚ»ªÉÏÊÐ
±±¾©2020Äê4ÔÂ21ÈÕ /ÃÀͨÉç/ -- Ç¿Éú¹«Ë¾ÔÚ»ªÖÆÒ©×Ó¹«Ë¾Î÷°²ÑîÉÖÆÒ©ÓÐÏÞ¹«Ë¾½üÈÕÐû²¼£¬ÆìÏÂÌØŵÑÅ ® £¨¹ÅÈûÆæÓȵ¥¿¹×¢ÉäÒº£¬Ó¢ÎÄÉÌÆ·Ãû£ºTREMFYA ® £¬Guselkumab£©ÒÑÔÚÖйúÉÏÊУ¬ÓÃÓÚÊʺÏϵͳÐÔÖÎÁƵÄÖÐÖضȰ߿é×´Òøм²¡³ÉÈË»¼Õß¡£ÌØŵÑÅ ® ÊÇ È«ÇòÊ׸ö »ñÅúµÄ°×½éËØ23£¨IL-23£©ÒÖÖƼÁ£¬¿ÉÒÔ°ÐÏòÒÖÖÆIL-23ÕâÖÖÔÚÒøм²¡ÖÐÆ𵽹ؼüÐÔ×÷ÓõÄϸ°ûÒò×Ó [1],[2] ¡£
2019Äê12ÔÂÔÚ»ñµÃÖйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©µÄ¼ÓËÙÉóÅúºó£¬ÌØŵÑÅ ®¼Ì¶øÀ´µ½Öйú¡£Æ䳤Ч³Ö¾ÃµÄƤËðÇå³ýЧ¹ûÒÑÔÚÈ«ÇòIIIÆÚÑо¿£¨VOYAGE 1¡¢VOYAGE 2£©Öеõ½Ö¤Êµ¡£Ñо¿±íÃ÷£¬Ïà½ÏÓÚ°²Î¿¼Á¶ÔÕÕ×éºÍTNFi¶ÔÕÕ×飬ÔÚµÚ16ÖÜ£¬ 73.3%£¨VOYAGE 1£©ºÍ70.0%£¨VOYAGE 2£©½ÓÊÜÌØŵÑÅ ®ÖÎÁƵĻ¼Õߣ¬ÆäƤËðÇå³ýÃæ»ý>90%£¨PASI 90£©£¬¶øTNFi¶ÔÕÕ×éÖ»ÓÐ49.7%£¨VOYAGE 1£©ºÍ46.8%£¨VOYAGE 2£©¡£ÔÚµÚ48ÖÜ£¬76%½ÓÊÜÌØŵÑÅ ®ÖÎÁƵĻ¼ÕßÈÔ¿Éά³ÖPASI 90Ó¦´ð¡£[3],[4]ͬʱ£¬ÔÚ³¤ÆÚËæ·ÃÖУ¬Ñо¿ÏÔʾ£¬Ê¹ÓÃÌØŵÑÅ ®ÖÎÁƵĻ¼Õß4ÄêÈÔ¿Éά³ÖÔÚPASI 90¸ßÓ¦´ð¡£
ÔÚÌØŵÑÅ ®µÄÁÙ´²Ñо¿ÖУ¬Ã»ÓÐÃ÷ÏÔÐźűíÃ÷»áÔö¼Ó¶ñÐÔÖ×Áö¡¢Ö÷ÒªÐÄѪ¹Ü²»Á¼Ê¼þ»òÑÏÖظÐȾµÄ·çÏÕ£¬×î³£¼ûµÄ²»Á¼·´Ó¦ÊÇÉϺôÎüµÀ¸ÐȾ¡£
ÌØŵÑÅ ®ÌåÏÖÁËÖÐÖضȰ߿é×´Òøм²¡ÖÎÁÆ·½°¸µÄÖØ´ó½ø²½£¬ÕýÈç±±¾©ÐºÍҽԺƤ·ô¿ÆÖ÷ÈνúºìÖнÌÊÚËù˵£¬IL-23ÊÇÒøм²¡Ö²¡Í¨Â·ºËÐĵ÷¿ØÒò×Ó£¬Í¨¹ý°ÐÏòÒÖÖÆIL-23£¬¶ÔÒøм²¡·¢²¡½øÐÐÕûÌåµ÷¿Ø£¬´Ó¶øʵÏÖ³¤Ð§³Ö¾ÃµÄƤËðÇå³ýЧ¹û¡£
¡°Òøм²¡»¼Õß³£³£ÒªÈÌÊÜÓɺì°ß¡¢ÁÛм¡¢Æ¤·ô·¢Ñ׶øÒýÆðµÄÉíÌåÌÛÍ´¡±£¬±±¾©´óѧÈËÃñҽԺƤ·ô¿ÆÖ÷ÈΡ¢ÖлªÒ½Ñ§»áƤ·ôÐÔ²¡Ñ§·Ö»áÇ°Ö÷ÈÎίԱÕŽ¨ÖнÌÊÚÖ¸³ö£¬¡°°ß¿é×´Òøм²¡¶Ô»¼ÕßÉú»îÖÊÁ¿ÓкܴóÓ°Ï죬²¢ÇÒ³£´øÀ´ÆäËûÑÏÖصĽ¡¿µÎÊÌ⣬ÀýÈçÌÇÄò²¡£¬ÐÄÔಡºÍÒÖÓôÖ¢µÈ¡£¡±
¡°ÓÉÓÚÒøм²¡ÂýÐÔ¡¢ÖÕÉíÐÔµÄÌص㣬»¼ÕßÐèÒª³¤ÆÚÖÎÁÆ£¬È´¾³£µ£ÐÄÓÉÓÚÒ©ÎïʧЧ¶ø´øÀ´µÄ¼²²¡¸´·¢ÎÊÌ⡱£¬Òøм²¡²¡ÓÑ»¥ÖúÍø´´Ê¼ÈËÊ·ÐÇÏèÏÈÉúÇ¿µ÷£¬¡°Òò´Ë£¬ÖÐÖضÈÒøм²¡»¼ÕßÒ²ÐèÒªÄܹ»Ìṩ³¤¾ÃÁÆЧµÄÖÎÁÆ·½°¸£¬ÒÔ³¤ÆÚ±£³ÖƤËðµÄÇå³ýЧ¹û¡£¡±
¡°ºÜ¸ßÐË¿´µ½ÌØŵÑÅ ®ÎªÖйúÒøм²¡»¼Õß´øÀ´ÖÎÁÆÐÂÑ¡Ôñ¡±£¬ÑîÉÈ«ÇòÑз¢ÃâÒß¼²²¡ÁìÓò¸±×ܲÃLloyd Miller²©Ê¿ËµµÀ£¬¡°ÖйúÓг¬¹ý100ÍòµÄÖÐÖضȰ߿é×´Òøм²¡»¼Õߣ¬ËûÃÇÕýÔÚÔâÊܼ²²¡´øÀ´µÄÍ´¿àÉõÖÁÊÇÖ²еÄÓ°Ï죬ÎÒÃDZØÐëÈ«Á¦ÒÔ¸°ÎªÌá¸ßËûÃǵÄÉú»îÖÊÁ¿¶ø²»¶ÏŬÁ¦¡£ÏàÐÅÌØŵÑÅ ®£¬ÕâÒ»´´ÐµÄÖÎÁÆ·½°¸¿ÉÒÔÂú×㻼Õßؽ´ý½â¾öµÄÖÎÁÆÐèÇó£¬Îª´ËÎҸе½·Ç³£×ÔºÀ¡£¡±
Î÷°²ÑîÉʼÖÕÖÂÁ¦ÓÚΪ×ÔÉíÃâÒß¼²²¡»¼Õߣ¬°üÀ¨Òøм²¡»¼Õߣ¬Ìṩ´´ÐµÄÉúÎïÖƼÁºÍÒ½Áƽâ¾ö·½°¸¡£Î÷°²ÑîÉÖÆÒ©ÓÐÏÞ¹«Ë¾×ܲÃAsgar Rangoonwala±íʾ£º¡°Î÷°²Ñîɽ«¼áÊسÐŵ£¬¼ÌÐøÓëÏà¹Ø»ú¹¹Í¨Á¦ºÏ×÷£¬ÎªÌáÉýÒ©Æ·¿É¼°ÐÔ¡¢Ô츣Öйú»¼Õ߶ø²»Ð¸Å¬Á¦¡£¡±
Ä¿Ç°£¬ÌØŵÑÅ ®ÒѽøÈëÖйú£¬¸²¸Ç±±¾©¡¢ÉϺ£¡¢¹ãÖÝ¡¢ÉîÛÚµÈ26¸ö³ÇÊС£Í¬Ê±£¬ÖйúºìÊ®×Ö»ù½ð»áÆô¶¯ÁË¡°ÌØÆôÐÂÉú¡±ÖÐÖضȰ߿é×´Òøм²¡»¼ÕßµÄÔ®ÖúÏîÄ¿£¬ÏòµÍÊÕÈëºÍµÍ±£µÄÖÐÖضȰ߿é×´Òøм²¡»¼ÕßÌṩÌØŵÑÅ ®£¨¹ÅÈûÆæÓȵ¥¿¹×¢ÉäÒº£©Ò©Æ·Ô®Öú¡£
ÖØÒª°²È«ÐÅÏ¢
Ïêϸ´¦·½ÐÅÏ¢£¬Çë¼û£º
[1] Tang C. et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases, Immunology. 2012 Feb; 135(2): 112 124. |
[2] Nawas Z. et al. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis. Skin Therapy Lett. 2017 Mar;22(2):8-10. |
[3] Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405-17. |
[4] Reich K and Armstrong A.W et al. J Am Acad Dermatol 2017;76(3):418 31. |
ÉÏһƪ£ºA.O.Ê·ÃÜ˹³øÏÂÀäÈÈÒ»Ì徻ˮ»ú È·±£¼ÒÍ¥ÒûË®°²È«±ã½Ý
ÏÂһƪ£º×îºóÒ»Ò³
¹óÖÝÀúÊ·
¹óÖÝÀúÊ·
¹óÖÝÀúÊ·
QQ¹«ÖںŹØ×¢
ÐÂÀË΢²©¹Ø×¢
΢ÐźÅ:dd_gzw
¹¤ÉÌÍø¼à
³£ÎñÀíÊÂ
¹«°²±¸°¸
¹¤ÐŲ¿±¸°¸
°²È«ÁªÃË
ʵÃûÈÏÖ¤